Skip to content

US · KYMR · BIOTECHNOLOGY

Kymera Therapeutics, Inc. (KYMR) intrinsic value and stock valuation

$115.31as of 2026-11-21 · Mkt cap 8.84B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Kymera Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values KYMR with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from KYMR’s statements →

Kymera Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Watertown, MA 02472 kymeratx.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$39.2M+2.9% 5y CAGRd
20182025
Net income
-$-311.4M
20182025
Free cash flow
-$-234.34M
20182025
Total equity
$1.58B+41% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$39.2M$47.1M$78.6M$46.8M$72.8M
Operating income-$-349.4M-$-261.63M-$-165.53M-$-161.26M-$-100.53M
Net income-$-311.4M-$-223.86M-$-146.96M-$-154.81M-$-100.22M
EPSd-$-3.69M-$-2.98M-$-2.52M-$-2.87M-$-2.09M
Operating cash flow-$-232.89M-$-194.5M-$-102.83M-$-153.09M-$-128.95M
Capital expenditure-$-1.45M-$-12.84M-$-34.48M-$-2.84M-$-1.6M
Free cash flow-$-234.34M-$-207.34M-$-137.31M-$-155.92M-$-130.54M
Total assets$1.74B$978M$575.8M$603.1M$605.9M
Total debt$82.3M$87.8M$84.7M$17.3M$18M
Net debt-$-274.76M-$-32.49M-$-25.29M-$-51.06M-$-30.01M
Total equity$1.58B$835.6M$395M$490.2M$459.6M
Cash and short-term investments$848.3M$488.7M$374.9M$407.2M$442.4M
Income statement
20252024202320222021
Revenue$39.2M$47.1M$78.6M$46.8M$72.8M
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$39.2M$47.1M$78.6M$46.8M$72.8M
Research and development expenses$316.6M$240.3M$189.1M$164.3M$137M
Selling, general and administrative expenses$68.2M$63.5M$55M$43.8M$36.3M
Other expenses$3.8M$4.92M$0.00$0.00$0.00
Operating expenses$388.6M$308.7M$244.1M$208.1M$173.4M
Cost and expenses$388.6M$308.7M$244.1M$208.1M$173.4M
Interest income$38M$38M$18.8M$6.62M$490K
Interest expense$250K$250K$200K$180K$170K
Depreciation and amortization$8.31M$7.37M$3.56M$2.98M$2.4M
Ebitda-$-303.06M-$-216.24M-$-143.2M-$-151.66M-$-97.64M
Operating income-$-349.4M-$-261.63M-$-165.53M-$-161.26M-$-100.53M
Total other income/expenses, net$37.8M$37.8M$18.6M$6.45M$310K
Income before tax-$-311.62M-$-223.86M-$-146.96M-$-154.81M-$-100.22M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-311.4M-$-223.86M-$-146.96M-$-154.81M-$-100.22M
Weighted average shares outstanding$84.4M$75M$58.4M$53.9M$48M
Weighted average diluted shares outstanding$84.4M$75M$58.4M$53.9M$48M
Balance sheet
20252024202320222021
Cash and short-term investments$848.3M$488.7M$374.9M$407.2M$442.4M
Net receivables$0.00$950K$18.8M$2.54M$140K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$871.2M$510.3M$405.3M$419.4M$451.3M
Property, plant and equipment, net$85.5M$97.9M$101.1M$22.2M$21.3M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$777M$362.2M$61.4M$152.3M$125.2M
Total non-current assets$871.6M$467.8M$170.4M$183.7M$154.6M
Total assets$1.74B$978M$575.8M$603.1M$605.9M
Accounts payable$4.01M$5.99M$7.08M$4.33M$4M
Short-term debt$13.8M$13.1M$6.34M$3.94M$3.6M
Deferred revenue$22.9M$13.6M$37.9M$35.3M$61.7M
Total current liabilities$83.2M$67.8M$85.7M$71.3M$92.5M
Long-term debt$68.5M$74.7M$78.3M$13.4M$14.4M
Deferred revenue, non-current$11.4M$0.00$16.8M$28M$39.3M
Total non-current liabilities$79.9M$74.7M$95.1M$41.6M$53.7M
Capital lease obligations$68.5M$87.8M$84.7M$17.3M$18M
Total liabilities$163.2M$142.4M$180.8M$113M$146.3M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-1.07B-$-754.61M-$-530.75M-$-383.79M-$-228.98M
Accumulated other comprehensive income (loss)$1.8M-$-1.49M-$-550K-$-4.95M-$-660K
Total equity$1.58B$835.6M$395M$490.2M$459.6M
Total investments$1.27B$730.7M$326.4M$491.1M$519.6M
Total debt$82.3M$87.8M$84.7M$17.3M$18M
Net debt-$-274.76M-$-32.49M-$-25.29M-$-51.06M-$-30.01M
Cash flow statement
20252024202320222021
Net income-$-311.35M-$-223.86M-$-146.96M-$-154.81M-$-100.22M
Depreciation and amortization$8.31M$7.37M$3.56M$2.98M$2.4M
Stock-based compensation$59.9M$55M$43.1M$35.5M$25M
Change in working capital$15.3M-$-23.97M$9.25M-$-37.62M-$-61.92M
Accounts receivable$950K$17.8M-$-16.23M-$-2.4M$580K
Inventory$0.00$0.00$0.00$2.4M$8.71M
Accounts payable-$-1.97M-$-310K$0.00$250K$50K
Net cash provided by operating activities-$-232.89M-$-194.5M-$-102.83M-$-153.09M-$-128.95M
Investments in property, plant and equipment-$-1.45M-$-12.84M-$-34.48M-$-2.84M-$-1.6M
Acquisitions, net$0.00$0.00$0.00-$-20.52M$5.81M
Net cash used for investing activities-$-521.06M-$-404.08M$139.9M$20.5M-$-99.83M
Common stock issued$992.2M$596.6M$0.00$149.8M$243.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$990.7M$608.9M$4.19M$153M$250.3M
Net change in cash$236.8M$10.3M$41.3M$20.4M$21.5M
Cash at end of period$362.8M$126.1M$115.8M$74.5M$54.1M
Operating cash flow-$-232.89M-$-194.5M-$-102.83M-$-153.09M-$-128.95M
Capital expenditure-$-1.45M-$-12.84M-$-34.48M-$-2.84M-$-1.6M
Free cash flow-$-234.34M-$-207.34M-$-137.31M-$-155.92M-$-130.54M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Kymera Therapeutics, Inc.

        Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

        CEO
        Nello Mainolfi
        Employees
        238
        Beta
        1.96

        Explore

        Frequently asked questions

        What is the intrinsic value of Kymera Therapeutics, Inc. (KYMR)?

        Kymera Therapeutics, Inc. (KYMR) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is KYMR undervalued?

        KYMR trades at a price of $115.31 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.